


# LIVERFAST™




## A Comprehensive MASLD/MASH Solution



### SIMPLE AND EASY TO DO

- 01** Physician prescribes LIVERFAST
- 02** Lab analyzes 10 biomarkers from 1 blood sample
- 03** Biomarker values plus age, height, weight and gender entered into platform
- 04** LIVERFAST results available immediately

### 1 BLOOD DRAW ► 3 SCORES ► 5 ADVANTAGES



Accurate Patient Monitoring For Better Liver Care

# From Detection to Drug-treatment Monitoring



## DESIGNED FOR LONGITUDINAL USE

Repeat testing supports structured follow-up without patient burden or procedural risk.

## TRACKS MEANINGFUL CHANGE OVER TIME

Quantifies shifts in fibrosis risk – helping detect improvement, stability, or progression earlier.

## SUPPORTS TREATMENT & LIFESTYLE IMPACT ASSESSMENT

Enables objective tracking of response to pharmacologic therapy or metabolic intervention.

## REDUCES DEPENDENCE ON REPEATED IMAGING

Provides an accessible monitoring tool between Fibroscan evaluations.



Part of Fibronostics' complete liver care framework:

Screening | **Monitoring** | Clinical Pathway | Ease of Use | Identification

## LIVERFAST has clear advantages in monitoring.

	LIVERFAST™	Fibroscan/VCTE	FIB-4
<b>Fibrosis Monitoring</b>	0.46 → 0.35 (p < 0.0001) ✓ Significant Improvement	10.1 → 8.3 kPa (p < 0.05) Lower sensitivity	1.83 → 2.01 (p = NS) No significant change
<b>Steatosis Monitoring</b>	0.47 → 0.42 (p < 0.05) ✓ Significant Reduction	302 → 293 dB/m (p = NS) NO significant change	 NO Steatosis Score
<b>Activity Monitoring</b>	 Tracking of current levels of liver inflammation	 NO Activity Score	 NO Activity Score

VCTE-Vibration-controlled transient elastography

## Monitoring needs to be:

Track fibrosis, steatosis, activity

Clinically Meaningful

Repeatable and easy to do

## LIVERFAST delivers

Classification of all 3 liver lesions

Dynamic sensitivity to pick up changes

1 blood draw, simple biomarkers

## 01 NO SPECIALIZED EQUIPMENT

Unlike Fibroscan, which requires hardware and trained technicians, LIVERFAST only needs a standard blood draw for fibrosis, steatosis and activity assessment.

## 02 ROBUST ACROSS ALL BODY TYPES

LIVERFAST remains accurate and reliable regardless of patient BMI or the presence of Type 2 Diabetes (T2DM).

## 03 GLOBAL REACH, LOCAL ACCESS

Ideal for primary care and metabolic clinics, allowing for large-scale population health monitoring without imaging bottlenecks.

## Clear Answers for MASLD/MASH Care.

Contact Us

888-552-1603 | [service@fibronostics.com](mailto:service@fibronostics.com)

[www.fibronostics.com](http://www.fibronostics.com)



FIBRONOSTICS US, INC.

615 Baronne St, Suite 100 New Orleans LA 70113